(Q38409259)

English

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

scientific article published on 24 October 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study (English)

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

multicenter clinical trial

0 references

systemic therapy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

object named as

Ritsuko Komaki

1 reference

Europe PubMed Central

23 December 2017

PMC publication ID

24

object named as

John V Heymach

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

George R Blumenschein

2

object named as

George R Blumenschein

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Stephen Swisher

23

object named as

Stephen G Swisher

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

18

object named as

Boris Sepesi

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Robert C Doebele

7

object named as

Robert C Doebele

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

6

object named as

D Ross Camidge

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Laurie E. Gaspar

9

object named as

Laurie E Gaspar

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

author name string

Daniel R Gomez

1

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

J Jack Lee

3

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Mike Hernandez

4

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Rong Ye

5

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Ferdinandos Skoulidis

8

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Don L Gibbons

10

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Jose A Karam

11

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Brian D Kavanagh

12

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Chad Tang

13

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Alexander V Louie

15

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

David A Palma

16

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Anne S Tsao

17

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

William N William

19

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Jianjun Zhang

20

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Qiuling Shi

21

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Xin Shelley Wang

22

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

publication date

24 October 2016

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

17

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

12

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

1672-1682

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

MicroRNA expression characterizes oligometastasis(es)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

Surgical treatment of oligometastatic non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

23 June 2018

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

The oligometastatic state - separating truth from wishful thinking

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Surgical treatment of primary lung cancer with synchronous brain metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

Surgical management of non-small cell lung cancer with synchronous brain metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5143183

31 August 2018

An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930532-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930532-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30532-0

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/5143183

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38409259&oldid=1872276366"